Benitec Biopharma (NASDAQ:BNTC) Releases Earnings Results, Beats Expectations By $0.01 EPS

Benitec Biopharma (NASDAQ:BNTC) released its earnings results on Friday. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01, FiscalAI reports.

Benitec Biopharma Trading Down 0.6%

NASDAQ BNTC traded down $0.05 on Friday, reaching $9.04. 144,689 shares of the company were exchanged, compared to its average volume of 148,826. The business’s fifty day moving average price is $9.74 and its 200 day moving average price is $11.41. The stock has a market capitalization of $315.41 million, a P/E ratio of -9.22 and a beta of 0.26. Benitec Biopharma has a fifty-two week low of $7.89 and a fifty-two week high of $14.39.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BNTC. Royal Bank Of Canada raised shares of Benitec Biopharma to an “outperform” rating in a research note on Tuesday, September 15th. HC Wainwright reaffirmed a “buy” rating on shares of Benitec Biopharma in a research note on Monday, November 2nd. Wall Street Zen cut shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, September 19th. Citigroup reiterated a “market outperform” rating on shares of Benitec Biopharma in a report on Tuesday, October 6th. Finally, Raymond James Financial began coverage on shares of Benitec Biopharma in a research note on Friday, October 23rd. They issued an “outperform” rating and a $14.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Benitec Biopharma has an average rating of “Moderate Buy” and a consensus price target of $22.00.

About Benitec Biopharma

Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines for serious diseases. Its approach uses DNA-directed RNA interference (ddRNAi), a technique designed to reduce the production of disease-causing proteins by directing cells to silence specific genes. The company’s lead investigational candidate, BB-301, is being developed for oculopharyngeal muscular dystrophy (OPMD), a rare inherited disorder that can cause progressive muscle weakness and difficulty swallowing.